SRC and cancer: Bosutinib (SKI-606), an Src inhibitor approved by the FDA for Philadelphia chromosome-positive leukemias (Ph+) (ClinicalTrials.gov Identifier: NCT00261846), is currently under evaluation for treating other cancers, including glioblastoma and lung cancer.